| Abstract | Interleukin 1 (IL1) plays an important role in adult onset Still's disease. Anakinra (Kineret), a recombinant IL1 Receptor Antagonist (IL 1 RA) was therefore recently proposed in adult onset Still's disease with great efficacy. Anakinra appeared to be well tolerated and safe. The case of a patient with refractory adult onset Still's disease who experienced a Systemic Inflammatory Response Syndrome and Adult Respiratory Distress Syndrome requiring intensive care unit hospitalization 10 days after the introduction of anakinra is reported. |
| Authors | S Guignard, G Dien, M Dougados
(Affiliation: Paris 5 Medicine Faculty, Cochin Hospital, Rheumatology B Department, Paris, France. sandra.guignard at free.fr)
|
| Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2007 Sep-Oct
Vol. 25
Issue 5
Pg. 758-9
ISSN: 0392-856X Italy |
| PMID | 18078628
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antirheumatic Agents
- Interleukin 1 Receptor Antagonist Protein
- Interleukin-1
|
| Topics |
- Adult
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Humans
- Interleukin 1 Receptor Antagonist Protein
(adverse effects, therapeutic use)
- Interleukin-1
(antagonists & inhibitors, physiology)
- Male
- Respiratory Distress Syndrome, Adult
(chemically induced)
- Still's Disease, Adult-Onset
(drug therapy, physiopathology)
- Systemic Inflammatory Response Syndrome
(chemically induced, diagnosis)
|
